DermTech Melanoma Test (2-GEP)
Early detection of melanoma in equivocal pigmented lesions
CommercialLaunched & Revenue Generating
Key Facts
Indication
Early detection of melanoma in equivocal pigmented lesions
Phase
Commercial
Status
Launched & Revenue Generating
Company
About DermTech
DermTech is a commercial-stage diagnostics company with a mission to elevate dermatologic care through non-invasive genomic testing. Its core achievement is the commercialization of the DermTech Melanoma Test, a laboratory-developed test (LDT) with a 99% negative predictive value, trusted by over 3,000 clinicians and used on over 300,000 patients. The company's 'DermTech 2.0' strategy focuses on operational execution, scaling commercial adoption, and securing payer coverage, primarily within the Medicare and Veterans Health Administration systems. DermTech generates revenue from test sales performed in its centralized, CLIA-certified lab.
View full company profile